Story thread · 2 reports / 2 sources
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
medcitynews.com · 7d
How the coverage leans
Across 2 sources · syndicated copies counted once
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .
First report: Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E — endpts.com, 7d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.